
Understanding, Diagnosing, and Using Genetic Testing for Thymoma
Tumors of the thymus can bring chest pain, cough and breathlessness, and often accompany myasthenia gravis. Imaging, biopsy and thymectomy are each explained.

MD · MBA
Physician specializing in genetic analysis and personalized preventive medicine, and author of Outsmart Your Genes.
Brandon Colby is a physician-expert in the fields of genetic analysis and Personalized Preventive Medicine. He holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University's Graduate School of Business, and a degree in Genetics from the University of Michigan.
Dr. Colby is the author of the book Outsmart Your Genes and has developed numerous technologies that improve the analysis, interpretation, and actionability of genome sequencing data. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (ACMG), an Associate of the American College of Preventive Medicine (ACPM), and a member of the National Society of Genetic Counselors (NSGC).
Articles by Brandon Colby, MD are reviewed for accuracy by Sequencing's medical and scientific team. This page is for informational purposes and does not constitute medical advice.

Tumors of the thymus can bring chest pain, cough and breathlessness, and often accompany myasthenia gravis. Imaging, biopsy and thymectomy are each explained.

A rapidly enlarging neck mass, hoarseness and trouble swallowing lead to imaging and needle biopsy. BRAF, TP53 and RAS results inform targeted therapy and prognosis.

Manage tooth agenesis, selective, 1 with genetic testing. Understand diagnosis, genetic causes, treatment plans, family planning, and associated conditions effectively.

Malformed outer ears, renal dysplasia and thumb or toe defects form the triad of TBS. SALL1 testing confirms it, and each child of an affected parent has a 50% chance.

Urothelial bladder cancer is worked up with imaging, cystoscopy and biopsy. FGFR3, TP53 and RB1 mutations inform targeted therapy, and ctDNA can track progression.

Without ER, PR or HER2 to target, this carcinoma resists hormonal and HER2 therapies. BRCA1 and BRCA2 results guide PARP inhibitors, family risk and surveillance.

Known also as malignant mixed Müllerian tumor, it is confirmed by biopsy, while TP53, PTEN and PIK3CA testing informs treatment choices and prognosis.

Uterine corpus cancer: early diagnosis, symptoms, and genetic testing. Learn how genetic mutations like BRCA1 & BRCA2 impact treatment and inform family risk.